FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers
Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.